Study summary · research use only
Thymosin alpha 1: past clinical experience and future promise
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review traces the clinical development history of thymosin alpha 1 in humans, from early studies with impure peptide mixtures under physician-sponsored INDs in patients with primary immune deficiencies such as DiGeorge syndrome, through to large phase-3 trials using synthetically produced thymosin alpha 1 involving hundreds of patients. The review describes this program as spanning multiple companies, indications, and countries, including the United States, Italy, and China, without reporting specific outcome data in this excerpt.
Abstract
Thymosin alpha 1, originally isolated as the compound responsible for reconstitution of immune function in thymectomized animal models, has enjoyed a wide-ranging clinical development program over the past decades, extending across multiple companies, indications, countries, and continents. This paper provides an overview of this complex picture. The extensive clinical studies began with small studies conducted with an impure mixture of peptides under the aegis of physician-sponsored INDs submitted to the US FDA, in subjects with primary immune deficiency such as DiGeorge syndrome. Subsequent studies ranged all the way to large phase-3 trials conducted with synthetically produced thymosin alpha 1 and hundreds of patients, in many countries including the United States, Italy, and China.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.